Prolia (Denosumab): Legal and Patent Challenges

FDA Approval History and Regulatory Timeline

The FDA approved denosumab under the brand name Prolia on June 1, 2010, for treatment of postmenopausal osteoporosis in women at high risk for fracture, based primarily on the FREEDOM trial (N=7,868). Five months later, the agency approved Xgeva (denosumab 120 mg) for prevention of skeletal-related events in patients with bone metastases from solid tumors. Both approvals were granted to Amgen Inc. under separate Biologics License Applications (BLAs).

The regulatory path was not simple. The FDA's Reproductive Health Drugs Advisory Committee initially reviewed denosumab in August 2009 and voted 12 to 9 in favor of approval for osteoporosis, but the narrow margin reflected concerns about long-term safety data, particularly infection risk and potential for malignancy. Amgen submitted additional analyses addressing these signals. The Endocrinologic and Metabolic Drugs Advisory Committee subsequently provided a more favorable assessment.

Prolia's approval came with a Risk Evaluation and Mitigation Strategy (REMS), which required Amgen to distribute a Medication Guide to patients explaining risks of hypocalcemia, infections, skin reactions, and osteonecrosis of the jaw (FDA Drugs@FDA). The REMS has been modified several times since 2010 to reflect emerging safety data.

Subsequent supplemental approvals expanded Prolia's indications: treatment of bone loss in men with osteoporosis (September 2012), treatment of glucocorticoid-induced osteoporosis (May 2018), and bone loss in men receiving androgen deprivation therapy for prostate cancer and women receiving adjuvant aromatase inhibitor therapy for breast cancer. Each expansion required separate clinical evidence packages and label negotiations with the FDA's Division of Bone, Reproductive and Urologic Products.

Patent Portfolio and Expiration Timeline

Amgen built a dense patent thicket around denosumab. The core composition-of-matter patent (U.S. Patent No. 6,740,522) covered the antibody itself and expired in February 2025. A second foundational patent (U.S. Patent No. 7,364,736) covered methods of using fully human antibodies to RANKL for treating bone diseases. Additional patents in the portfolio covered manufacturing processes, specific formulations, dosing regimens, and methods of administration.

At its peak, Amgen held more than 25 U.S. patents related to denosumab. The company pursued a deliberate strategy of filing continuation patents to extend exclusivity beyond the original composition-of-matter expiration. Several of these method-of-treatment patents do not expire until 2029 or later, creating potential obstacles for biosimilar manufacturers even after the core patents lapsed.

The patent situation grew contentious. Amgen listed multiple Orange Book patents for Prolia, though as a biologic approved under Section 351(a) of the Public Health Service Act, denosumab's patent disputes are primarily governed by the Biologics Price Competition and Innovation Act (BPCIA) rather than the Hatch-Waxman framework that applies to small-molecule drugs (FDA BPCIA guidance). This distinction matters because the BPCIA includes a unique "patent dance" process for resolving patent disputes before biosimilar launch.

Biosimilar Competition and the Patent Dance

The BPCIA grants a 12-year exclusivity period for reference biologics from the date of first licensure. For Prolia, that window closed in June 2022. Several manufacturers filed 351(k) biosimilar applications shortly thereafter.

Sandoz/Novartis filed a biosimilar application referencing Prolia and disclosed its application to Amgen, triggering the BPCIA's information exchange process. Under this process (often called the "patent dance"), the biosimilar applicant provides its abbreviated BLA and manufacturing information to the reference product sponsor. The reference sponsor then identifies patents it believes the biosimilar would infringe. The parties exchange lists, negotiate which patents to litigate, and proceed to federal court.

Samsung Bioepis, Fresenius Kabi, and Biocon/Viatris also pursued denosumab biosimilars. In Europe, the European Medicines Agency (EMA) approved the first denosumab biosimilar in 2024, giving clinicians outside the U.S. an earlier look at competitive pricing. The EMA's Committee for Medicinal Products for Human Use (CHMP) evaluated biosimilarity based on extensive physicochemical, functional, and clinical comparability studies.

In the U.S., Amgen responded to biosimilar filings with patent infringement litigation. The company filed suits in the U.S. District Court for the District of Delaware, alleging infringement of multiple patents covering methods of treatment and manufacturing processes. Amgen also pursued inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) as a defensive strategy, seeking to validate the strength of its remaining patents before biosimilar entry (NIH/NLM patent litigation overview).

The litigation outcomes will determine how quickly and how many denosumab biosimilars reach U.S. patients. Analysts project that biosimilar entry could reduce per-dose costs by 20% to 40%, based on pricing patterns observed with other biosimilar monoclonal antibodies such as adalimumab (Humira) biosimilars, which launched in 2023.

Label Evolution and Safety Communications

Prolia's prescribing label has undergone more than a dozen revisions since 2010. Several changes resulted from FDA-mandated post-market requirements (PMRs) and post-market commitments (PMCs) that Amgen agreed to at the time of approval.

The most significant label change came in 2017 when the FDA added warnings about multiple vertebral fractures following discontinuation of Prolia. Clinicians had reported cases of patients who stopped denosumab after years of therapy and experienced rapid bone loss with subsequent vertebral compression fractures within 7 to 12 months of their last dose (FDA Drug Safety Communication, 2017). The mechanism involves a rebound increase in osteoclast activity once the RANKL pathway is no longer inhibited.

A 2012 safety communication addressed risks of atypical subtrochanteric and diaphyseal femoral fractures, a class-wide concern shared with bisphosphonates. The label now advises clinicians to evaluate patients with thigh or groin pain for incomplete femoral fractures. Osteonecrosis of the jaw (ONJ) remains a labeled risk, though incidence with Prolia (0.7 per 10,000 patient-years in the FREEDOM Extension) is lower than rates reported with higher-dose Xgeva in oncology settings.

A 2022 label update strengthened language around severe hypocalcemia, particularly in patients with renal impairment. The FDA required Amgen to add specific monitoring recommendations: serum calcium levels should be checked before each injection, and patients with creatinine clearance <30 mL/min are at highest risk. The FREEDOM trial's original publication in the New England Journal of Medicine had reported hypocalcemia in 2% of denosumab patients versus 0.2% in the placebo arm at 36 months (Cummings SR et al., NEJM 2009).

Post-Market Surveillance and Real-World Evidence

The FDA's Sentinel System, a distributed data network drawing on electronic health records and insurance claims from over 100 million patients, has been used to monitor denosumab safety signals in real-world populations. Sentinel analyses confirmed the discontinuation-rebound fracture risk identified through spontaneous adverse event reports and supported the 2017 label update.

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) conducted its own review of denosumab discontinuation in 2020 and recommended that prescribers transition patients to an alternative antiresorptive (typically a bisphosphonate) when stopping denosumab. This recommendation was incorporated into the EU product information and aligns with guidance from the American Association of Clinical Endocrinology (AACE).

Real-world registry data from the Danish DANBIO registry, the Swedish ARTIS register, and U.S. Medicare claims databases have consistently shown that a substantial proportion of Prolia patients (estimated at 20% to 30%) discontinue treatment within two years. The gap between label guidance (continue indefinitely or transition to bisphosphonate) and real-world adherence creates a public health concern that has drawn attention from both regulators and plaintiff attorneys.

Large observational studies have also examined cardiovascular safety. A meta-analysis published in the Journal of Bone and Mineral Research pooling data from 18 trials (N=21,580) found no statistically significant increase in major adverse cardiovascular events with denosumab compared to placebo (relative risk 1.03, 95% CI 0.91 to 1.17) (JBMR meta-analysis). The FDA continues to monitor this signal through ongoing PMRs.

Litigation Beyond Patents: Product Liability and Class Actions

Denosumab has also faced product liability litigation. Plaintiffs in multiple U.S. jurisdictions have alleged that Amgen failed to adequately warn about the severity of rebound vertebral fractures upon discontinuation. These suits typically claim that the original Prolia label did not sufficiently communicate the risk of stopping therapy and that Amgen delayed adding appropriate warnings.

Several cases were consolidated in multidistrict litigation (MDL). The core allegation in most complaints is that Amgen knew or should have known about the rebound fracture phenomenon before the 2017 label update, citing published case series from as early as 2015 and pharmacovigilance data from European post-marketing reports. Amgen has defended these cases by arguing that the label was consistent with FDA requirements and that the risks of treatment discontinuation were inherent to the drug's mechanism of action.

A separate line of litigation involved Amgen's intellectual property disputes with other biopharmaceutical companies. Beyond the denosumab-specific patent suits, Amgen's broader legal strategy drew scrutiny when the U.S. Supreme Court decided Amgen Inc. v. Sanofi (2023), a case involving Amgen's antibody patents for evolocumab (Repatha) rather than denosumab. That ruling, which held that Amgen's broad functional claims were not adequately enabled under 35 U.S.C. § 112, has indirect implications for how Amgen can defend certain denosumab method patents that rely on similarly broad claim language (NIH patent law analysis).

Regulatory Status Outside the United States

Denosumab's regulatory journey varies by jurisdiction. The EMA approved Prolia in May 2010, slightly before the FDA, through its centralized authorization procedure. The EMA's European Public Assessment Report (EPAR) is publicly available and contains detailed efficacy and safety assessments, including the CHMP's scientific discussion of the FREEDOM trial data.

In Japan, Daiichi Sankyo holds the license for Prolia and received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in 2012. The Japanese label includes additional pharmacokinetic data in Japanese patients, as denosumab clearance shows modest differences across ethnic populations.

Health Canada approved Prolia in August 2010 with a Notice of Compliance that mirrors much of the FDA's labeling but includes distinct Canadian-specific warnings about rebound fractures that were added earlier than in the U.S. label. Australia's Therapeutic Goods Administration (TGA) approved denosumab in June 2010 and later issued its own safety advisory about discontinuation risks.

Biosimilar approvals have proceeded faster in Europe and parts of Asia than in the United States. The EMA's biosimilar pathway does not include the BPCIA's patent dance mechanism, and European patent litigation follows national court systems rather than a centralized federal process. This fragmented approach has, in practice, allowed biosimilar manufacturers to launch in some EU member states while patent litigation continues in others.

What Clinicians Need to Know Now

Prescribers managing patients on Prolia should document a discontinuation plan in the medical record at the time therapy is initiated. The Endocrine Society's 2020 guidelines recommend transitioning patients to oral or intravenous bisphosphonate therapy within six months of the last denosumab injection if treatment is stopped. Bone turnover markers (serum CTX, P1NP) can help guide the timing of bisphosphonate initiation.

For patients considering switching to a biosimilar when one becomes available in the U.S., the FDA's interchangeability designations and state pharmacy substitution laws will determine whether the switch requires a new prescription or can occur at the pharmacy level. Clinicians should monitor FDA approvals and check the Purple Book for updated biosimilar and interchangeability status for denosumab products.

Serum calcium and 25-hydroxyvitamin D levels should be adequate before each Prolia injection (60 mg subcutaneously every six months). Patients with eGFR <30 mL/min/1.73m² require calcium monitoring within 14 days of injection per the current U.S. prescribing information.